Arcturus Therapeutics is trading 10.03% down at $13.19, with no clear company-specific announcement or event explaining the October 6 decline; broader biotech weakness is the likeliest context, though no direct cause is established.
- XBI was reported down about 2.5% during the session, while broader U.S. indexes were higher.
- Recent coverage instead referenced earlier clinical data and analyst commentary.